
Pheno Therapeutics heads towards human testing of MS therapy
Biotechnology company Pheno Therapeutics has announced that the US Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for its lead therapeutic candidate PTD802 targeting multiple sclerosis (MS). The clearance follows a clinical trial authorisation (CTA) from the UK’s MHRA at the start… Read More

